|
APN
APN
APN - Aspen - Key Arv Products Viread* And Truvada* Registered By Mcc
ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
Registration number 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
("Aspen" or "the Company")
KEY ARV PRODUCTS VIREAD* AND TRUVADA* REGISTERED BY MCC
JSE listed Aspen, a leading global manufacturer and distributor of Anti-
Retroviral (ARV) Medicines, today announced that it has been granted
certification from the Medicines Control Council of South Africa (MCC) to
manufacture and distribute the two key ARV products Viread* (tenofovir
disoproxil fumarate) and Truvada* (emtricitabine and tenofovir disoproxil
fumarate) in the South African market. This certification enables
immediate availability of these two products to South African patients,
particularly the many hundreds that have been receiving treatment with
these medicines under the special named patient exemption permitted by MCC.
Both Viread and Truvada have extensive usage in North America, Europe and
some African countries. Last week both products were included in the World
Health Organisation`s revised Essential Medicines List.
The registration of Viread and Truvada follows the non-exclusive
manufacturing, licensing, technology transfer and distribution agreement
which Aspen entered into in 2005 with leading research-based
biopharmaceutical company Gilead Sciences, Inc. (Nasdaq: GILD). Under this
agreement, Aspen will manufacture and distribute these products for all 53
African countries.
On receipt of the certification, Aspen Group CE, Stephen Saad said, "Both
Viread and Truvada represent significant advantages for patients to
existing first line ARV treatments, for example patient compliance is
enhanced through simpler and more convenient dosing, and Viread and Truvada
do not seem to exhibit some of the unwanted side effects that place
patients at increased risk of other morbidities with some of the other
ARVs."
Saad went on to comment that, "Tenofovir is now the most prescribed
molecule for the treatment of HIV/AIDS patients in the United States, and
the MCC`s certification means that South African patients can now begin to
enjoy the same benefits as patients have in the developed world, but at
significantly reduced prices. The market availability of Viread and Truvada
has been long anticipated by South African patients, particularly given the
scale up of AIDS treatment in South Africa and many existing and new South
African patients now stand to benefit from this certification, in a country
when the total number of infected HIV patients is the second highest in the
world."
24 April 2007
Sponsor:
Investec Bank Limited
* Registered Trademark
Date: 24/04/2007 12:55:23 Produced by the JSE SENS Department.
| Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information. | |||||||||||||
| Other Profile Group sites: FundsData Online (unit trust data) | Profile Group corporate site | |||||||||||||
| [ Terms of Use | Privacy Policy | PAIA manual | FAQs/Help | Site Map | © Copyright Reserved 2026 ] | |||||||||||||
|
|||||||||||||
